These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38835773)

  • 41. Role of cellular events in the pathophysiology of sepsis.
    Bhan C; Dipankar P; Chakraborty P; Sarangi PP
    Inflamm Res; 2016 Nov; 65(11):853-868. PubMed ID: 27392441
    [TBL] [Abstract][Full Text] [Related]  

  • 42. TREML4: a Potential Target for Immunotherapy of Sepsis.
    Huang SJ; Li ZL; Ma XL; Du B; Wang JL
    Discov Med; 2021; 32(166):87-92. PubMed ID: 35219349
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis.
    Rudick CP; Cornell DL; Agrawal DK
    Expert Rev Clin Immunol; 2017 Sep; 13(9):907-919. PubMed ID: 28742984
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Damage- and pathogen-associated molecular patterns and alarmins: keys to sepsis?
    Denk S; Perl M; Huber-Lang M
    Eur Surg Res; 2012; 48(4):171-9. PubMed ID: 22653136
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunosuppression following surgical and traumatic injury.
    Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Miyazaki M
    Surg Today; 2010 Sep; 40(9):793-808. PubMed ID: 20740341
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of circulating lymphocytes in patients with sepsis.
    de Pablo R; Monserrat J; Prieto A; Alvarez-Mon M
    Biomed Res Int; 2014; 2014():671087. PubMed ID: 25302303
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting Immune Cell Checkpoints during Sepsis.
    Patil NK; Guo Y; Luan L; Sherwood ER
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29135922
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pulmonary Innate Immune Response Determines the Outcome of Inflammation During Pneumonia and Sepsis-Associated Acute Lung Injury.
    Kumar V
    Front Immunol; 2020; 11():1722. PubMed ID: 32849610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Implications of Lymphatic Transport to Lymph Nodes in Immunity and Immunotherapy.
    Thomas SN; Rohner NA; Edwards EE
    Annu Rev Biomed Eng; 2016 Jul; 18():207-33. PubMed ID: 26928210
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of sepsis: current status of clinical immunotherapy.
    O'Callaghan A; Redmond HP
    Surgeon; 2006 Dec; 4(6):355-61. PubMed ID: 17152200
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sirtuin1 Targeting Reverses Innate and Adaptive Immune Tolerance in Septic Mice.
    Martin AN; Alexander-Miller M; Yoza BK; Vachharajani V; McCall CE
    J Immunol Res; 2018; 2018():2402593. PubMed ID: 30069485
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
    Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
    J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony.
    Monneret G; Venet F; Pachot A; Lepape A
    Mol Med; 2008; 14(1-2):64-78. PubMed ID: 18026569
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early Immune Function and Duration of Organ Dysfunction in Critically III Children with Sepsis.
    Muszynski JA; Nofziger R; Moore-Clingenpeel M; Greathouse K; Anglim L; Steele L; Hensley J; Hanson-Huber L; Nateri J; Ramilo O; Hall MW
    Am J Respir Crit Care Med; 2018 Aug; 198(3):361-369. PubMed ID: 29470918
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recurrent Sepsis Exacerbates CD4
    He W; Xiao K; Xu J; Guan W; Xie S; Wang K; Yan P; Fang M; Xie L
    Front Immunol; 2021; 12():627435. PubMed ID: 33717146
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment?
    Prucha M; Zazula R; Russwurm S
    Arch Immunol Ther Exp (Warsz); 2017 Feb; 65(1):37-49. PubMed ID: 27554587
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dysregulation of the immune response in severe sepsis.
    Pinsky MR
    Am J Med Sci; 2004 Oct; 328(4):220-9. PubMed ID: 15486537
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Autophagy in cancer immunotherapy: Perspective on immune evasion and cell death interactions.
    Yu Q; Ding J; Li S; Li Y
    Cancer Lett; 2024 May; 590():216856. PubMed ID: 38583651
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sepsis immunopathology: perspectives of monitoring and modulation of the immune disturbances.
    Skirecki T; Borkowska-Zielińska U; Złotorowicz M; Hoser G
    Arch Immunol Ther Exp (Warsz); 2012 Apr; 60(2):123-35. PubMed ID: 22301668
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Host innate immune responses to sepsis.
    Wiersinga WJ; Leopold SJ; Cranendonk DR; van der Poll T
    Virulence; 2014 Jan; 5(1):36-44. PubMed ID: 23774844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.